ECSP045493A - Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a - Google Patents

Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a

Info

Publication number
ECSP045493A
ECSP045493A EC2004005493A ECSP045493A ECSP045493A EC SP045493 A ECSP045493 A EC SP045493A EC 2004005493 A EC2004005493 A EC 2004005493A EC SP045493 A ECSP045493 A EC SP045493A EC SP045493 A ECSP045493 A EC SP045493A
Authority
EC
Ecuador
Prior art keywords
pharmaceutical compositions
compositions containing
polymorph
flibanserine
new pharmaceutical
Prior art date
Application number
EC2004005493A
Other languages
English (en)
Inventor
Thomas Friedl
Guido Bernhard Edmund Radtke
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of ECSP045493A publication Critical patent/ECSP045493A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invención se refiere a composiciones farmacéuticas orales que contienen flibanserina, métodos para su preparación y su uso como medicamento.
EC2004005493A 2002-05-22 2004-12-13 Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a ECSP045493A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02011224 2002-05-22

Publications (1)

Publication Number Publication Date
ECSP045493A true ECSP045493A (es) 2005-03-10

Family

ID=29433081

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005493A ECSP045493A (es) 2002-05-22 2004-12-13 Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a

Country Status (25)

Country Link
EP (1) EP1511489B1 (es)
JP (1) JP3919788B2 (es)
KR (1) KR101054237B1 (es)
CN (3) CN102240289A (es)
AT (1) ATE499939T1 (es)
BR (1) BRPI0311189B8 (es)
CA (1) CA2483597C (es)
CY (1) CY1111470T1 (es)
DE (1) DE60336225D1 (es)
DK (1) DK1511489T3 (es)
EA (1) EA007185B1 (es)
EC (1) ECSP045493A (es)
ES (1) ES2361994T3 (es)
HR (1) HRP20041092B1 (es)
IL (1) IL164440A0 (es)
ME (1) MEP55308A (es)
MX (1) MXPA04011487A (es)
NO (1) NO329414B1 (es)
NZ (1) NZ537253A (es)
PL (1) PL211062B1 (es)
RS (1) RS51718B (es)
SI (1) SI1511489T1 (es)
UA (1) UA80135C2 (es)
WO (1) WO2003097058A1 (es)
ZA (1) ZA200408151B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183410B2 (en) 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
US20060264511A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of drug-induced sexual dysfunction
US20060264512A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of sexual dysfunction due to medical conditions
JP2009503020A (ja) 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥満症の治療におけるフリバンセリンの使用
CA2626134C (en) 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
EP2037927B1 (en) * 2006-06-30 2010-01-27 Boehringer Ingelheim International GmbH Flibanserin for the treatment of urinary incontinence and related diseases
JP5793828B2 (ja) 2006-08-14 2015-10-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング フリバンセリンの製剤及びその製造方法
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
KR20090045945A (ko) 2006-08-25 2009-05-08 베링거 인겔하임 인터내셔날 게엠베하 제어 방출 시스템 및 이의 제조방법
ATE524446T1 (de) 2006-12-20 2011-09-15 Boehringer Ingelheim Int Sulfatierte benzimidazolon-derivate mit gemischter serotonin-rezeptor-affinität
EP1955699A1 (en) * 2007-02-08 2008-08-13 Boehringer Ingelheim Pharma GmbH & Co. KG Use of flibanserin for the treatment of insomnia
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
EP2090297A1 (en) * 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formulations of flibanserin
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
CN104926734B (zh) * 2015-07-07 2017-04-05 苏州立新制药有限公司 氟班色林的制备方法
CN108699007A (zh) * 2016-01-31 2018-10-23 孟晓明 氟班色林的新晶型及其制备方法及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
UA76767C2 (uk) * 2001-08-02 2006-09-15 Бідакем С.П.А. Стабільна поліморфна модифікація флібансерину, спосіб її промислового одержання та її застосування для одержання лікарських засобів
DE10138273A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Arzneimittel mit neuroprotektiver Wirkung

Also Published As

Publication number Publication date
BR0311189A (pt) 2005-02-22
BRPI0311189B8 (pt) 2021-05-25
JP3919788B2 (ja) 2007-05-30
PL211062B1 (pl) 2012-04-30
ES2361994T3 (es) 2011-06-27
EA007185B1 (ru) 2006-08-25
UA80135C2 (en) 2007-08-27
SI1511489T1 (sl) 2011-06-30
IL164440A0 (en) 2005-12-18
JP2005530787A (ja) 2005-10-13
NZ537253A (en) 2007-09-28
KR20040111668A (ko) 2004-12-31
MEP55308A (en) 2011-05-10
EP1511489A1 (en) 2005-03-09
DK1511489T3 (da) 2011-05-02
KR101054237B1 (ko) 2011-08-08
PL372457A1 (en) 2005-07-25
EP1511489B1 (en) 2011-03-02
CN1655789A (zh) 2005-08-17
CN101002780A (zh) 2007-07-25
WO2003097058A1 (en) 2003-11-27
NO329414B1 (no) 2010-10-18
CA2483597A1 (en) 2003-11-27
NO20044547L (no) 2004-12-17
ATE499939T1 (de) 2011-03-15
HRP20041092A2 (en) 2005-06-30
AU2003240672A1 (en) 2003-12-02
RS98704A (sr) 2006-12-15
DE60336225D1 (de) 2011-04-14
CN102240289A (zh) 2011-11-16
CA2483597C (en) 2010-02-09
EA200401515A1 (ru) 2005-06-30
RS51718B (sr) 2011-10-31
ZA200408151B (en) 2006-06-28
BRPI0311189B1 (pt) 2019-04-09
MXPA04011487A (es) 2005-02-14
HRP20041092B1 (hr) 2013-05-31
CY1111470T1 (el) 2015-08-05

Similar Documents

Publication Publication Date Title
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
BR0015188A (pt) Composições farmacêuticas
UA96449C2 (en) Stable laquinimod preparations
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
SE0001899D0 (sv) New compounds
ITMI20031570A1 (it) Composizione per uso dietetico, farmaceutico o cosmetico
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.
NO20062605L (no) Farmasoytisk formulering inneholdende smakssubstanser med forbedrede farmasoytiske egenskaper
ECSP066291A (es) Sistemas emulsionantes que contienen derivados de azetidina
TW200503785A (en) Dosage form containing (S)-pantoprazole as active ingredient
NO20064808L (no) Orale matrixformuleringer med licarbazepin
TW200503783A (en) Oral pharmaceutical preparation for proton pump antagonists
MX2009008813A (es) Composicion farmaceutica que contiene floroglucinol y paracetamol.
EA200601015A1 (ru) Пероральные композиции дезоксипеганина и их применение
NO20064783L (no) Opplosningstabeletter med licarbazepin
TNSN08242A1 (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
ECSP066292A (es) Sistemas semi-sólidos que contienen derivados de azetidina
ATE357220T1 (de) Pharmazeutische zusammensetzung mit modifizierter freisetzung
DK1399143T3 (da) Anvendelsen af Acetyl L-carnitin til fremstilling af et lægemiddel til behandling af anhedoni
UY27824A1 (es) Nueva formulación para la administración parenteral de crobenetina.
IL162857A0 (en) Oral vaccination
TNSN06299A1 (en) Oral matrix formulations comprising licarbazepine